Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population

Clinical Chemistry

Volumn 46, Issue 1, 2000, Pages 18-23

  Garcia Barceló, Mercè ^a   Chow, Lok Yee ^a   Chiu, Helen Fung Kum ^a   Wing, Yun Kowk ^a   Lee, Dominic Tak Shing ^a   Lam, Kwok Lim ^a   Waye, Mary Miu Yee ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE 4 HYDROXYLASE; DNA; NEUROLEPTIC AGENT; RESTRICTION ENDONUCLEASE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLELE; ARTICLE; CHINESE; DRUG METABOLISM; ENZYME ACTIVITY; GENE; GENETIC POLYMORPHISM; GENOTYPE; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

EID: 0033965373     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.1.18     Document Type: Article

References (28)

1. 1. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez F. The human debrisoquine 4-hydroxylase (CYP2D6) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989;45:889-904.
2. 2. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995;29:192-209.
3. 3. Johansson I, Oscarsson M, Yue Q-Y, Bertilsson L, Sjövist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450 locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
4. 4. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989:46:198-207.
5. 5. Sohn D-R, Shin S-G, Park C-W, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991;32:504-7.
6. 6. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
7. 7. Dahl M-L, Yue Q-Y, Roh H-K, Johansson I, Säwe J, Sjövist F, Bertilsson L. Genetic analysis of the CYP2D6 locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5:159-64.
8. 8. Roh H-K, Dahl M-L, Johansson I, Ingelman-Sundberg M, Cha Y-M, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996:6:441-7.
9. 9. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
10. 10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994:317-92.
11. 226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 1996;6:269-72.
12. 12. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM. Characterization and PCR based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996:6:319-28.
13. 13. Bottema CDK, Sommer SS. PCR amplification of specific alleles: Rapid detection of known mutations and polymorphism. Mutat Res 1993:288:93-102.
14. 14. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
15. 15. Daly AK, Steen VM, Fairbrother KS, Idle JR. CyP2D6 multiallelism. Methods Enzymol 1996:272:199-210.
16. 16. Marez D, Legrand M, Sabbaagh N, Lo Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 Cyp2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
17. 17. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997;52: 1034-40.
18. 18. Lee EJD, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994;37:605-7.
19. 19. Broly F, Marez D, Sabbaagh N, Legrand M, Millecamps S, Lo Guidice JM, et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995;5:373-84.
20. 20. Wang SL, Lai MD, Huang JD. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab Dispos 1999;27:385-8.
21. 21. Heim HH, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336: 529-32.
22. 22. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, et al. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996:5:395-441.
23. 23. Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharmacol Res 1998;15:517-24.
24. 24. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997:60:284-95.
25. 25. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjövist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90: 11825-9.
26. 26. Lundqvist E, Johansson J, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 1999:226:327-38.
27. 27. Wang SL, Lai MD, Lai ML, Huang JD. R296C and other CYP2D6 mutations in Chinese. Pharmacogenetics 1995;5:385-8.
28. 28. Chen S, Chou W-H, Blouin RA, Mao Z, Humphries LL, Meek QC, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence in clinical outcomes in psychiatry. Clin Pharm Ther 1996;5:522-34.